Emerging markers in cardiovascular disease: Where does angiotensin‐converting enzyme 2 fit in?
- 29 July 2013
- journal article
- review article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 40 (8), 551-559
- https://doi.org/10.1111/1440-1681.12069
Abstract
The fulltext of this publication will be made publicly available after relevant embargo periods have lapsed and associated copyright clearances obtained.The renin-angiotensin system plays a major role in the pathophysiology of cardiovascular disease (CVD). The enzyme angiotensin-converting enzyme (ACE) converts angiotensin (Ang) I into the vasoconstrictor AngII and was thought, until recently, to be the main effector of the system. The enzyme ACE2, discovered in 2000, can counterbalance the effects of ACE through degradation of AngII and generation of Ang-(1-7). Angiotensin-converting enzyme 2 is abundantly expressed in the heart and localized to the endothelial cells of coronary vessels and smooth muscle cells. Its catalytically active ectodomain undergoes shedding, resulting in ACE2 in the circulation. There are 10 studies to date that have measured circulating ACE2 activity in humans, including in healthy subjects and those with heart failure, Type 1 diabetes, implantable cardioverter/defibrillator, elderly subjects undergoing emergency orthopaedic surgery and kidney transplant patients. The results suggest that circulating ACE2 activity may be a marker of CVD, with low levels in healthy individuals and increased levels in those with cardiovascular risk factors or disease. Whether increased plasma ACE2 activity reflects increased synthesis from tissue ACE2 mRNA or increased shedding of tissue ACE2 remains to be determined. Angiotensin-converting enzyme 2 is located on the X-chromosome and circulating ACE2 levels are higher in men than in women. Large clinical studies in CVD are needed to more precisely clarify the role of ACE2 as a biomarker of CVD, determine the prognostic significance of circulating ACE2 activity and assess whether the measurement of ACE2 will improve CVD risk prediction.Restricted Access: Metadata OnlKeywords
This publication has 59 references indexed in Scilit:
- Angiotensin-Converting Enzyme 2: The First DecadeInternational Journal of Hypertension, 2011
- Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assaysAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2011
- Reciprocal changes in renal ACE/ANG II and ACE2/ANG 1–7 are associated with enhanced collecting duct renin in Goldblatt hypertensive ratsAmerican Journal of Physiology-Renal Physiology, 2011
- Angiotensin-(1–7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomyClinical Science, 2010
- Plasma ACE2 Activity is an Independent Prognostic Marker in Chagas' Disease and Equally Potent as BNPJournal of Cardiac Failure, 2010
- Soluble Angiotensin-Converting Enzyme 2 in Human Heart Failure: Relation With Myocardial Function and Clinical OutcomesJournal of Cardiac Failure, 2009
- Ectodomain shedding of angiotensin converting enzyme 2 in human airway epitheliaAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart Failure: Insights Into the Endogenous Counter-Regulatory Pathway of the Renin-Angiotensin-Aldosterone SystemJournal of the American College of Cardiology, 2008
- Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin systemAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2007
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationThe New England Journal of Medicine, 2004